| Outcome Measures: |
Primary: Difference between renal medullary perfusion after administration of BAY 2327949 and placebo as assessed by arterial spin labelling magnetic resonance imaging (ASL-MRI), 2-way crossover design Participants Arm 1: Single dose of BAY2327949 + 7 days washout phase + Single dose of Placebo Participants Arm 2: Single dose of Placebo + 7 days washout phase + Single dose of BAY2327949, Within 2 hours of treatment | Secondary: Difference between T1 (renal water content) after administration of BAY 2327949 and placebo, 2-way crossover design Participants Arm 1: Single dose of BAY2327949 + 7 days washout phase + Single dose of Placebo Participants Arm 2: Single dose of Placebo + 7 days washout phase + Single dose of BAY2327949 T1 = (renal water content) (unit: ms) acquired during MRI scanning (this parameter will only be obtained at two timepoints, baseline and after the perfusion assessments, and not for all multimodal MRI assessments), Within 2 hours of treatment|Difference between T2* in the kidney cortex after administration of BAY 2327949 and placebo, 2-way crossover design Participants Arm 1: Single dose of BAY2327949 + 7 days washout phase + Single dose of Placebo Participants Arm 2: Single dose of Placebo + 7 days washout phase + Single dose of BAY2327949 T2 = (unit: ms) acquired during MRI scanning, Within 2 hours of treatment|Difference between T2* in the kidney medulla after administration of BAY 2327949 and placebo, 2-way crossover design Participants Arm 1: Single dose of BAY2327949 + 7 days washout phase + Single dose of Placebo Participants Arm 2: Single dose of Placebo + 7 days washout phase + Single dose of BAY2327949 T2 = (unit: ms) acquired during MRI scanning, Within 2 hours of treatment|Difference between renal cortical perfusion after administration of BAY 2327949 and placebo, 2-way crossover design Participants Arm 1: Single dose of BAY2327949 + 7 days washout phase + Single dose of Placebo Participants Arm 2: Single dose of Placebo + 7 days washout phase + Single dose of BAY2327949, Within 2 hours of treatment|Difference between renal arterial flow after administration of BAY 2327949 and placebo, 2-way crossover design Participants Arm 1: Single dose of BAY2327949 + 7 days washout phase + Single dose of Placebo Participants Arm 2: Single dose of Placebo + 7 days washout phase + Single dose of BAY2327949, Within 2 hours of treatment|Number of participants with treatment-emergent adverse events (TEAEs), Up to 21 days
|
